The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial
Open accessAbstract
Background: Proinflammatory cytokines, especially tumour necrosis factor α (TNF-α), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF-α synthesis, may represent a novel and rational approach to the treatment of cancer cachexia. Aims: To assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer. Methods: Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status. Results: Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm 3 in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference −2.59 kg (95% confidence interval (CI) −4.3 to −0.8); p = 0.005) and 4.46 cm 3 (absolute difference −5.6 cm 3 (95% CI −8.9 to −2.2); p = 0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm 3 in AMA compared with a loss of 3.62 kg (absolute difference −3.57 kg (95% CI −6.8 to −0.3); p = 0.034) and 8.4 cm 3 (absolute difference −7.9 cm 3 (95% CI −14.0 to −1.8); p = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain ( r = 0.56, p = 0.001). Conclusion: Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Tisdale, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc927 · Cited by 982
Heymsfield, S., McManus, C., Smith, J., Stevens, V, & Nixon, D. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.4.680 · Cited by 824
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Tumors secreting human TNF/cachectin induce cachexia in mice
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A., & Socher, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90028-6 · Cited by 640
Fearon, K. C. H. (2003) · Gut · doi:10.1136/gut.52.10.1479 · Cited by 603
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Barber, M. D., Ross, J. A., Voss, A. C., Tisdale, M. J., & Fearon, K. C. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690654 · Cited by 459
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Tisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Thomas, D. R. (2007) · Clinical Nutrition · doi:10.1016/j.clnu.2007.03.008 · Cited by 521
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Oxidative Stress, Chronic Disease, and Muscle Wasting
Moylan, J. S., & Reid, M. B. (2007) · Muscle & Nerve · doi:10.1002/mus.20743 · Cited by 416
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413
“The secondary end point, weight, requires cautious interpretation because, in contrast to other trials lasting 8 to 12 weeks or longer, this trial was only 6 weeks long; however, in some of those trials, weight gain was observed after 4 weeks.(47,48) The degree of weight loss in our patients was lower (11.”
ResultDodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319
Fatigue in palliative care patients — an EAPC approach
Radbruch, L., Strasser, F., Elsner, F., Gonçalves, J. F., Løge, J., Kaasa, S., Nauck, F., Stone, P., & the Research Steering Committee of the European Association for Palliative Care (EAPC) (2008) · Palliative Medicine · doi:10.1177/0269216307085183 · Cited by 317
Cancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273
Crawford, J., Prado, C. M. M., Johnston, M. A., Gralla, R. J., Taylor, R. P., Hancock, M. L., & Dalton, J. T. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0522-0 · Cited by 178
Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.
Shadfar, S., Couch, M. E., McKinney, K. A., Weinstein, L. J., Yin, X., Rodríguez, J. E., Guttridge, D. C., & Willis, M. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.563032 · Cited by 98
“These include high-dose progestins ( 59 ), eicosapentaenoic acid (EPA) ( 60 ), β-hydroxy-β-methylbutyrate (HMB) ( 61 ), thalidomide ( 62 ), and NSAIDs ( 63 ).”
Mueller, T. C., Bachmann, J., Prokopchuk, O., Friess, H., & Martignoni, M. E. (2016) · BMC Cancer · doi:10.1186/s12885-016-2121-8 · Cited by 95
Karagianni, V. T., Papalois, A. E., & Triantafillidis, J. K. (2012) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-012-0189-4 · Cited by 43
Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part II
Wilczynski, J., Duechler, M., & Czyz, M. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0132-3 · Cited by 41
Perioperative Nutritional Aspects in Total Pancreatectomy: A Comprehensive Review of the Literature
Furbetta, N., Comandatore, A., Gianardi, D., Palmeri, M., Di Franco, G., Guadagni, S., Caprili, G., Bianchini, M., Fatucchi, L. M., Picchi, M., et al. (2021) · Nutrients · doi:10.3390/nu13061765 · Cited by 18
“Cytokines could also play a role in cachexia [56,57], as pro-inflammatory cytokines interfere in cachexia mechanisms so that the inhibition of these cytokines could improve BMI by reducing weight loss in pancreatic cancer [22,58].”
Background
Metadata
- Authors
- Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T., & Goggin, P. M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-03-07
- Volume
- 54
- Issue
- 4
- Pages
- 540-545
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1975230416
- Cited by
- 322
- References
- 40
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.